By: Christopher Parrella, Esq., CPC, CHC, CPCO

Parrella Health Law, Boston, MA

A Health Care Provider Defense and Compliance Firm

The FDA’s Pharmacy Compounding Advisory Committee has handed the peptide industry a significant advisory victory, but health care providers should not mistake the vote for regulatory approval. On July 23 and 24, 2026, the committee recommended that six peptides be considered for inclusion on the Section 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. The committee rejected Emideltide, also known as DSIP. The votes were divided. BPC-157, KPV, and TB-500 passed 8 to 6. MOTS-c passed 7 to 5. Epitalon passed 7 to 4. Semax passed 8 to 5. Emideltide failed 6 to 7. 

The decision is notable because the FDA’s own scientific staff recommended against adding every one of the seven substances. FDA evaluated BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Semax for cerebral ischemia, migraine and trigeminal neuralgia, Epitalon for insomnia, and Emideltide for opioid withdrawal, chronic insomnia and narcolepsy. The agency’s briefing materials cited limited evidence of effectiveness, unresolved safety questions, and problems identifying exactly which chemical form would be compounded.

BPC-157 illustrates the concern. FDA found that the name is used for multiple salts and derivatives with different active components. The agency warned that inconsistent naming could result in a patient receiving a different bulk substance than the prescriber intended. FDA also found that neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug.

The committee’s recommendation is advisory and nonbinding. It does not add any peptide to the 503A list today. It does not make the products FDA-approved, and it does not establish that they are safe or effective. FDA must still make a final regulatory decision. Until that occurs, pharmacies, telehealth platforms, longevity clinics, med spas, and prescribers should not treat the vote as an independent legal authority to compound, dispense, or market these substances. Even if the FDA ultimately adds the peptides to the 503A list, compounded products will remain unapproved drugs. The FDA does not conduct premarket review of compounded drugs for safety, effectiveness, or quality. Section 503A also requires patient-specific prescriptions and imposes sourcing, certificate-of-analysis, and other statutory conditions. State pharmacy and medical practice laws will continue to apply. 

This is where providers face immediate compliance risk. Social media demand will move faster than FDA rulemaking. Patients may hear that “FDA said yes” while marketers describe these products as approved, validated, or clinically proven. Those claims would confuse an advisory recommendation with FDA approval. The FDA has specifically warned that compounded drugs should not be promoted in ways that falsely suggest they have satisfied the agency’s approval standards. 

The call to action is clear. Do not launch a peptide program based solely on an advisory vote. Review every proposed substance, source, formulation, indication, and route of administration with experienced regulatory counsel. Confirm the lawful federal and state compounding pathway. Tighten informed consent, adverse-event response, prescribing documentation, and vendor oversight. Scrub advertising so it never implies FDA approval or proven effectiveness.

The peptide market may be opening, but the regulatory risk is opening with it. If you have questions about peptide prescribing, pharmacy compounding, or wellness program compliance, please contact Parrella Health Law at 857.328.0382 or Chris directly at cparrella@parrellahealthlaw.com.